Pombiliti (cipaglucosidase alfa) Medical Benefit Medication Utilization Policy
Customize your policy alerts
Sign up for all Community-Care policy alerts
Know when Community-Care releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical-benefit coverage, prior authorization, quantity limits, and continuation criteria for cipaglucosidase alfa (Pombiliti) used to treat late-onset Pompe disease for members covered by the payer.
No material clinical or coverage changes in this revision.
Coverage Criteria for Pombiliti (cipaglucosidase alfa)
Initial Therapy
Covered when ALL of the following are met for initial approval:
Continuation Therapy
Covered when ALL of the following are met for continuation:
This policy covers cipaglucosidase alfa (Pombiliti) for late-onset Pompe disease only when specific conditions are met. For initial approval, the member must have a clinical diagnosis of late-onset Pompe disease confirmed by genetic sequencing OR an acid alpha-glucosidase enzyme assay, the prescription must come from a medical geneticist or neuromuscular specialist, the enzyme replacement therapy must be co-prescribed with miglustat (Opfolda), and the patient must be experiencing symptoms or objective signs of Pompe disease. These elements must all be documented in the prior authorization request.
For continuation of therapy, coverage will be approved when the member has an established diagnosis of late-onset Pompe disease and there is documentation that the member is benefiting from therapy, is being monitored, and is appropriate to continue therapy. Requests for ongoing authorization must include evidence of clinical benefit and monitoring consistent with specialist management.
Initial Therapy — Detailed Criteria
Initial therapy criteria
Continuation Therapy — Detailed Criteria
Continuation criteria
Continuation will be approved when the member demonstrates benefit and appropriate monitoring.
Coding and Dosing Information
| J1203 | Injection, cipaglucosidase alfa-atga, 5 mg |
Quantity Limits and Dosing Requirements
Provider Requirements, Prior Authorization, and Documentation
Prior authorization required — include diagnostic confirmation, prescriber specialty, miglustat co‑prescription, symptoms, and weight
Prior authorization is required for cipaglucosidase alfa (J1203). The PA must include documentation confirming the diagnosis (genetic sequencing OR acid alpha‑glucosidase enzyme assay), the prescribing specialist (medical geneticist or neuromuscular specialist), that cipaglucosidase alfa is prescribed with miglustat (Opfolda), evidence of symptoms or objective signs, and the member's weight for dosing.
- Include diagnostic confirmation by genetic sequencing or acid alpha‑glucosidase enzyme assay.
- Confirm prescriber specialty: medical geneticist or neuromuscular specialist.
- Document that miglustat (Opfolda) is co‑prescribed with cipaglucosidase alfa.
- Provide evidence of symptoms or objective signs of Pompe disease.
- Provide member weight for dosing calculation (authorization requires weight).
Provider action highlights — specialist prescriber, co‑prescription with miglustat, and objective evidence required
Providers must ensure the prescription is written by an appropriate specialist and that miglustat is co‑prescribed; submit objective evidence of disease and the patient's weight with the request to avoid processing delays.
- Prescription must be from a medical geneticist or neuromuscular specialist.
- Cipaglucosidase alfa must be prescribed together with miglustat (Opfolda).
- Provide objective signs or documented symptoms of Pompe disease.
Documentation specifics — diagnostic confirmation, prescriber specialty, prescription details, symptoms, and weight
Submit documentation confirming late‑onset Pompe disease by genetic sequencing OR acid alpha‑glucosidase enzyme assay, the prescriber's specialty (medical geneticist or neuromuscular specialist), the complete prescription details including co‑prescription of miglustat (Opfolda), evidence of symptoms or objective signs, and the patient's weight for dosing.
- Diagnostic test result: genetic sequencing OR acid alpha‑glucosidase enzyme assay.
- Prescriber specialty documented (medical geneticist or neuromuscular specialist).
- Prescription details showing cipaglucosidase alfa given with miglustat (Opfolda).
- Clinical documentation of symptoms or objective signs of Pompe disease.
- Patient weight (required for dosing: up to 20 mg/kg every 2 weeks).
Denial risks — missing diagnostic proof, incorrect prescriber specialty, or no miglustat co‑prescription
Requests lacking required diagnostic confirmation, not authored by an appropriate specialist, or without documentation that cipaglucosidase alfa is prescribed with miglustat may be denied.
- Absence of genetic sequencing OR acid alpha‑glucosidase enzyme assay confirming diagnosis.
- Prescriber is not a medical geneticist or neuromuscular specialist.
- No documentation that miglustat (Opfolda) is co‑prescribed with cipaglucosidase alfa.
- Missing evidence of symptoms or objective signs, or missing patient weight for dosing.
Key Definitions
Clinical Background
Pompe disease (glycogen storage disease type II) is an inherited deficiency of the lysosomal enzyme acid alpha-glucosidase that leads to progressive accumulation of glycogen in muscle tissue, resulting in progressive skeletal and respiratory muscle weakness. Late-onset Pompe disease typically presents with progressive limb-girdle and respiratory muscle weakness and a variable clinical course. Cipaglucosidase alfa is an enzyme replacement therapy indicated for treatment of late-onset Pompe disease and, per this policy, must be prescribed together with miglustat (Opfolda) when used for this indication.
Step Therapy Requirements
| Step | Requirement |
|---|---|
| Step 1 | Covered when ALL of the following are met for initial approval: (1) Clinical diagnosis of late‑onset Pompe disease confirmed by genetic sequencing OR acid alpha‑glucosidase enzyme assay; (2) Prescribed by a medical geneticist or neuromuscular specialist; (3) Cipaglucosidase alfa is prescribed with miglustat (Opfolda); (4) Patient is experiencing symptoms or objective signs of Pompe disease. |
Site of Care Considerations
Site‑of‑care note — include patient weight; dose authorization tied to weight-based limit
Site‑of‑care information: authorization includes a weight requirement for approval and quantity limits of up to 20 mg/kg every 2 weeks; include member weight on the PA to support site‑of‑care dosing and authorization.
- Quantity limit if approved: up to 20 mg/kg every 2 weeks.
- A weight is required for approval and must be submitted with the authorization request.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.